This innovative therapy is proven to be highly effective for patients with blood cancers such as lymphoma, myeloma and acute lymphoblastic leukemia (ALL) and is also being explored as a treatment for other cancers including breast, gastric and kidney cancers.
“In my new role at Icon I’m dedicated to improving the availability of this treatment option, and ultimately providing the best possible care for our patients,” said Dr Nath.
“My research interest includes exploring ways to make CAR T-cell therapy safer, with fewer side effects and I look forward to the opportunity to grow Icon’s capabilities in this space.”
Group Medical Director, Dr Ian Irving said this marks a step forward in Icon’s ongoing commitment to investing in research and advancing cancer care.
“We’re very pleased to welcome back Karthik who started his career with Icon and has since made significant contributions to the cancer care profession,” said Dr Irving.
“Karthik will help enhance our strong research offering with a focus on exploring cellular therapy clinical trials and providing direction and advocacy for increased access to cellular therapies particularly in Australia’s private healthcare sector.”
This appointment has been made possible by the generous contribution of an anonymous donor to not-for-profit charity, Icon Cancer Foundation whose mission is to promote, initiate and fund innovative research to give cancer patients and communities a better, brighter and healthy future.
